Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

NCT04322383 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Hairy Cell Leukemia

Interventions

DRUG: binimetinib

Sponsor

National Cancer Institute (NCI)